Paclitaxel-Based Chemotherapy for Non–Small Cell Lung Cancer: Predicting the Response with 99mTc-Tetrofosmin Chest Imaging

Journal of Nuclear Medicine

Chia-Hung Kao¹  Shih-Chuan Tsai¹  Yung-Jen Ho¹  Sheng-Ping ChangLai¹  Jong-Kang Lee¹  Jih-Fang Hsieh¹ 

[1] Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung; Department of Nuclear Medicine, Chi-Mei Foundation Hospital, Tainan; Department of Nuclear Medicine, Show-Chwan Hospital, Changhua; Department of Radiology, Jen-Ai Hospital, Taichung; Department of Nuclear Medicine, Chung-Shan Medical and Dental College, Taichung; and Department of Nuclear Medicine, China Medical College Hospital, Taichung, Taiwan Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung; Department of Nuclear Medicine, Chi-Mei Foundation Hospital, Tainan; Department of Nuclear Medicine, Show-Chwan Hospital, Changhua; Department of Radiology, Jen-Ai Hospital, Taichung; Department of Nuclear Medicine, Chung-Shan Medical and Dental College, Taichung; and Department of Nuclear Medicine, China Medical College Hospital, Taichung, Taiwan Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung; Department of Nuclear Medicine, Chi-Mei Foundation Hospital, Tainan; Department of Nuclear Medicine, Show-Chwan Hospital, Changhua; Department of Radiology, Jen-Ai Hospital, Taichung; Department of Nuclear Medicine, Chung-Shan Medical and Dental College, Taichung; and Department of Nuclear Medicine, China Medical College Hospital, Taichung, Taiwan

关键词: ^99mTc-tetrofosmin;    non–small cell lung cancer;    chemotherapy;    multidrug resistance–mediated P-glycoprotein;   

DOI  :  

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

The purpose of this study was to retrospectively predict the chemotherapeutic response to paclitaxel for non–small cell lung cancer (NSCLC) using 99mTc-tetrofosmin (TF) uptake and to detect the expression of 170-kDa multidrug resistance–mediated P-glycoprotein (MDR-Pgp). Methods: Before chemotherapy with paclitaxel, 20 patients with stage IIIb or IV NSCLC were enrolled in this study to undergo early and delayed 99mTc-TF chest imaging for calculating tumor-to-normal lung ratios (T/NL) and retention indices (RI) for assessment of the MDR-Pgp in NSCLC. Results: The early and delayed mean T/NLs were 1.59 ± 0.25 and 1.50 ± 0.25, respectively, for 10 patients with a good response and 1.09 ± 0.09 and 1.03 ± 0.05, respectively, for 10 patients with a poor response. The differences were shown to be significant (P < 0.001) by independent Student t tests. However, no significant differences (P = 0.801) between good-response patients (−5.70% ± 3.67%) and poor-response patients (−5.23% ± 4.51%) were found in RI. In addition, other prognostic factors (age, sex, tumor size, stage, and cell type) were not significantly different between good-response patients and poor-response patients. Conclusion: 99mTc-TF chest images are potential tools for understanding MDR-Pgp expression in NSCLC and for predicting the chemotherapeutic response to paclitaxel.

【 授权许可】

Unknown